A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
04/01/2022at 09:27

Analyst to focus on Bavarian Nordic, Novo Nordisk and Lundbeck in 2022

Søren Løntoft Hansen, senior analyst at Sydbank, will be keeping a particularly close eye on the three companies to see how they deal with clinical results, promising candidates and production problems.
Photo: Philip Davali/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, translated by catherine brett

A new year means a new set of challenges for Denmark's life science companies, which are followed closely by Sydbank senior analyst Søren Løntoft Hansen, who has his sights trained on Bavarian Nordic, Novo Nordisk and Lundbeck in 2022.

Bavarian Nordic is expected to release further phase II results for its Covid-19 vaccine ABNCoV2 and start a phase III trial of the candidate this year.

"There will probably be some news on that in the second half of 2022. They are also starting their RSV study, though data probably will not be released until 2023. But in connection with this, it will be interesting to see what conversations they are having with potential partners, and whether we will see a partnership agreement at some point in 2022," says Løntoft Hansen.

Bavarian Nordic announced a capital funding round at the end of 2021 in order to fund a phase III study of the company's RSV vaccine candidate in the first half of 2022. CEO Paul Chaplin also announced that potential partners will be considered alongside the clinical study, which is expected to last a year.

Bavarian Nordic's share price increased by 43 percent in 2021.

Spotlight on production problems at Novo Nordisk

Løntoft Hansen will also be keeping a close eye on Denmark's largest pharmaceutical company, Novo Nordisk, which had a very positive 2021 in terms of share price, boasting a 71 percent value increase.

The analyst expects the underlying development for this new level of growth to continue, and says that quarterly performance will influence the share price.

However, he also highlights the problems the company has faced in 2021, which are expected to carry through into the new year. This includes a new insulin tender model in China, which led Novo Nordisk to announce in November that it expects sales growth to decrease by 3 percent in 2022.

Novo Nordisk also experienced problems with its newly launched obesity drug Wegovy in 2021. The most recent hurdle was the announcement in December that the syringe manufacturer for the Wegovy injection pens had temporarily stopped production. Novo Nordisk therefore does not expect to meet patient demand for Wegovy in the US until the second half of 2022.

"Of course, it will be exciting to see how and when they solve this problem, and whether they will bounce back enough in terms of production and supply to be able to meet patient demand in 2022. That will be very exciting," says Løntoft Hansen, who does not expect Novo Nordisk to have as good a year as last year when it comes to share price.

"I still think the share will perform well, but you probably shouldn't bank on a 70 percent return from it. It would really surprise me if that happened in 2022."

All eyes on Lundbeck candidate

Compared to Bavarian Nordic and Novo Nordisk, Lundbeck had a significantly more challenging 2021, as its share price dropped 20 percent.

However, it is still worth keeping an eye on the company in 2022, as Lundbeck is expected to release phase III results for its candidate Rexulti, which aims to treat agitation in Alzheimer's patients in the middle of the year.

"Their late-stage pipeline is still narrow, and needs to be strengthened, when you consider the risk associated with it. But there is no doubt that phase III results for Rexulti are a share trigger," says Løntoft Hansen.

Lundbeck and its partner Otsuka chose to continue the phase III study in April last year, based on an independent analysis of preliminary results. The companies chose to enroll 330 people in the study, meaning it ran at full capacity, rather than stopping the study at 255 patients.

"We introduced this component to the study because the medical need is huge, and we wanted to have the opportunity to take an early look at the data and see whether the candidate had a sufficiently strong effect to allow us to culminate the study early. It did not," Lundbeck's research and development head Johan Luthman told MedWatch at the time.

Bavarian Nordic's spending on factory expansion exceeds USD 150m

Analyst: Novo Nordisk was expected to complete acquisition – despite issues 

Director at Lundbeck: "Some whistleblowers write in a way that makes it completely impossible to investigate anything at all" 

Related articles:

  • Photo: Bavarian Nordic / PR

    Bavarian Nordic's spending on factory expansion exceeds USD 150m

    For subscribers

  • Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

    Analyst: Novo Nordisk was expected to complete acquisition – despite issues

    For subscribers

  • Photo: Jens Dresling

    Director at Lundbeck: "Some whistleblowers write in a way that makes it completely impossible to investigate anything at all"

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Photo: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Principal Laboratory Technologist

  • Head of International Sales

  • Commercial Director

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Experienced Patent Counsel

  • Application Manager

  • Clinical Operational Associate

  • Head of Regulatory Affairs Danmark

  • Senior Regulatory Affairs Professional

See all jobs

Jobs

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Principal Laboratory Technologist

  • Head of International Sales

  • Commercial Director

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Experienced Patent Counsel

  • Application Manager

  • Clinical Operational Associate

  • Head of Regulatory Affairs Danmark

  • Senior Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge